FPA
TBPH icon

First Pacific Advisors’s Theravance Biopharma TBPH Stock Holding History

First Pacific Advisors’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-176,539
Closed -$1.6M – 196
2022
Q2 		$1.6M Buy
176,539
+36,765
+26% +$339K 0.02% 100
2022
Q1 		$1.34M Buy
+139,774
New +$1.37M 0.02% 99

Other funds holding TBPH

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Pacific Advisors's TBPH Position: Q3 2022 in Review

First Pacific Advisors sold out of Theravance Biopharma (TBPH) in Q3 2022, closing a stake of 176,539 shares — an estimated $1.6M sold.

First Pacific Advisors first reported a position in TBPH in Q1 2022 and held it in 2 quarters. The position peaked at $1.6M in Q2 2022. 123 funds tracked by Wall St. Rank hold TBPH as of Q3 2022.

  • First Pacific Advisors reported no remaining Theravance Biopharma position as of Q3 2022 after selling out during the quarter.
  • First Pacific Advisors sold 176,539 Theravance Biopharma shares in Q3 2022, an estimated $1.6M.
  • First Pacific Advisors first reported a position in Theravance Biopharma in Q1 2022 and held it in 2 quarters.
  • First Pacific Advisors's Theravance Biopharma position peaked at $1.6M in Q2 2022.
  • 123 funds tracked by Wall St. Rank held Theravance Biopharma as of Q3 2022.

Based on First Pacific Advisors's 13F filing for Q3 2022, filed 4 Nov 2022.